BML (4694) Q4 2026 earnings summary

Executive summary

• Net sales rose 4.9% year-over-year to ¥150,262 million, with operating profit up 11.3% and profit attributable to owners up 23.7%.

• Growth was driven by new customer acquisitions, price optimization, and improved profitability across core segments, including clinical testing, food hygiene, and medical informatics.

• Strategic investments in next-generation laboratories and DX initiatives are progressing ahead of schedule.

Financial highlights

• Net sales increased by ¥7,071 million year-over-year; operating profit up ¥1,057 million (11.3%).

• EBITDA rose 14.5% to ¥19,334 million; ordinary profit up 10.5% to ¥11,014 million.

• Gross profit grew to ¥48,689 million from ¥45,861 million year-over-year.

• Cash and cash equivalents at year-end were ¥64,602 million, up ¥673 million from the prior year.

• Dividend per share for FY2025 was ¥125.00, with a payout ratio of 66.9%.

Outlook and guidance

• FY2026 forecast: net sales of ¥155,000 million (+3.2%), operating profit of ¥10,500 million (+0.8%), and profit attributable to owners of parent of ¥7,000 million (-9.7%).

• Depreciation to peak in FY2026 due to accelerated new building operations.

• Company aims to improve profitability through service fee adjustments and operational efficiency.

• Ninth Medium-Term Management Plan targets enhanced quality, solutions, and mutual development.